Participants 126 179 5
very high-risk childhood acute lymphoblastic leukemia
Participants 182 445 4
PURPOSE To determine whether the use of a recombinant human granulocyte colony-stimulating factor ([G-CSF] lenogastrim) can increase the chemotherapy dose-intensity (CDI) delivered during consolidation chemotherapy of childhood acute lymphoblastic leukemia (ALL).
Participants 446 620 7
PATIENTS AND METHODS Sixty-seven children with very high-risk ALL were randomized (slow early response to therapy, 55 patients; translocation t(9;22) or t(4;11), 12 patients)
